| Document |
Document Title |
|
WO/2012/059797 |
Improved process for the synthesis of (S)-pregabalin having more than 99% ee through (S) 3-cyano-5-methyl-hexanoic acid has been developed. In addition to above, a novel process for resolution of (RS) - 3-cyano-5-methyl-hexanoic acid thr...
|
|
WO/2012/061093 |
Esteramine compositions and their derivatives are disclosed. The esteramines comprise a reaction product of a metathesis-derived C10-C17 monounsaturated acid, octadecene-1,18-dioic acid, or their ester derivatives with a tertiary alkanol...
|
|
WO/2012/055014 |
Phenylketone carboxylate compounds of Formula I, wherein n=2-6; R=C(0); -OC(O)- or -CH( OH)-; A is (CH2)mCOOH, W(CH2)mCOOH or YCH(COOH)((CH2)pCH3) when B is Ft B is (CH2)mCOOH, W(CH2)mCOOH or YCH(COOH)((CH2)pCH3) when A is Ft or A snd B ...
|
|
WO/2012/055455 |
The invention pertains to a new route to prepare β-functionalized carboxylic acid esters in a one-pot reaction, by reacting an olefinic acid ester in the presence of a catalyst system, comprising a Rh(I)-complex, together with an aryl b...
|
|
WO/2012/055991 |
The present invention relates to a complex of two divalent metal cations and a chelating agent chosen from the group of EDDHA (ethylenediamine-N,N'-di-(hydroxyphenyl acetic acid)), EDDHMA (ethylenediamine-N,N'-di-(hydroxy- methylphenyl a...
|
|
WO/2012/051741 |
Glycin derivatives of formula (I) are provided, in which R1 represents C1-C4 alkyl, R2 represents H or methyl and n represents an integer of 1-6. The above compounds have the activity of inhibiting melanin production and can be used in c...
|
|
WO/2012/046771 |
The inventors have intensively studied on compounds that have Aβ42 production inhibitory activity and have found that a compound (I) of the present invention, wherein a carboxylic acid or a tetrazole group is bonded to a cycloalkane moi...
|
|
WO/2012/048043 |
Disclosed herein are processes for making L-ornithine phenyl acetate. The process may include, for example, intermixing a halide salt of L-ornithine with silver phenyl acetate. The process may also include forming a phenyl acetate salt i...
|
|
WO/2012/039775 |
A buccal delivery system is disclosed suitable for delivery of a therapeutic agent to the oral cavity of a patient. The delivery system comprises a matrix for containing and releasing the therapeutic agent into the oral cavity and an alk...
|
|
WO/2012/040646 |
The present invention can involve a method of synthesizing α-amino-ε-caprolactam. The method can comprise heating a salt of L-lysine in a solvent comprising an alcohol under Super Critical Fluid conditions. The methods can comprise hea...
|
|
WO/2012/037665 |
There is provided compositions and methods for the treatment of respiratory conditions such as pulmonary hypertension and sickle-cell disease in a patient in need thereof. The composition and method are for treating a patient in need the...
|
|
WO/2012/034065 |
The present invention provides aliskiren intermediates and impurities, and processes for preparation thereof. The present invention also provides processes for preparing aliskiren using these intermediates and impurities. These impuritie...
|
|
WO/2012/033187 |
The present invention pertains to a method for producing optically active 2-aminobutyric acid containing a step for obtaining a diastereometric salt of optically active 2-aminobutyric acid and optically active tartaric acid by combining ...
|
|
WO/2012/031736 |
The invention relates to a process for the production of L-carnitine tartrate, wherein the L-carnitine tartrate is precipitated from a reaction mixture comprising L-carnitine and tartaric acid dissolved in ethanol, the ethanol having a w...
|
|
WO/2012/033097 |
[Problem] To provide a method for producing complex crystal quantum crystals encapsulating plasmon metal quantum dots. [Solution] Quantum crystals are produced by a method characterized in that an aqueous plasmon metal complex solution f...
|
|
WO/2012/033188 |
A method for producing an optically active amino acid, said method comprising heating an amino acid and an optically active carboxylic acid together with an aldehyde in an organic solvent, and then adding an amine to the organic solvent ...
|
|
WO/2012/032035 |
The invention relates to salts of acids with 2-propyl esters of general formula (2) The invention also relates to a method for the preparation of salts of acids with compounds of general formula (2) and to the use thereof in the preparat...
|
|
WO/2012/032185 |
The invention relates to a method for producing crystalline 5-aminosalicylic acid with a particularly high tap and/or bulk density.
|
|
WO/2012/028721 |
The invention refers to a process for the reductive amination of α-keto carboxylic acids catalyzed by transition metal containing compounds.
|
|
WO/2012/025464 |
This invention relates to deuterated tyrosine derivatives labeled with 18 F or 19 F, methods of preparing such compounds, compositions comprising such compounds, kits thereof and uses of such compounds, compositions or kits for imaging p...
|
|
WO/2012/024233 |
In various embodiments, the present invention provides zwitterionic lipids, encapsulants incorporating these zwitterionic lipids and such encapsulants encapsulating one or more bioactive agent. An exemplary bioactive agent is a nucleic a...
|
|
WO/2012/024611 |
Provided are methods that include administration of beta-alanine for the treatment of muscular disorders and for the improvement of muscle function. Among the methods provided are methods for maintaining muscle strength and function (e.g...
|
|
WO/2012/016849 |
Suggested is a new process for the selective hydrogenation of (poly)unsaturated hydrocarbons, in particular polyunsaturated fatty acid alkyl esters into the respective saturated and/or mono-unsaturated species, of aldehydes into respecti...
|
|
WO/2012/018095 |
The purpose of the present invention is to provide a production process which can synthesize a bicyclo[2.2.2]octylamine derivative represented by general formula (1) or a salt thereof with high efficiency and in a large quantity. The pre...
|
|
WO/2012/013673 |
The invention relates to a compound of the formula (I), in which R1, R2 independently of each other are a C1-C6 alkyl radical or H or together are a C5-C7 alkyl radical, R3, R4 independently of each other are an organic radical containin...
|
|
WO/2012/016184 |
A lipid particle can include a cationic lipid. The cationic lipid can include one or more hydrophobic tails, which can include one or more sites of unsaturation. The sites of unstaturation can include cycloalkyl groups, e.g., cyclopropyl...
|
|
WO/2012/016184 |
A lipid particle can include a cationic lipid. The cationic lipid can include one or more hydrophobic tails, which can include one or more sites of unsaturation. The sites of unstaturation can include cycloalkyl groups, e.g., cyclopropyl...
|
|
WO/2012/012278 |
Disclosed are compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically related to GPR35, and/or GPR35-hERG signaling complex. For example, disclosed are compounds for preventing and/or treat...
|
|
WO/2012/010297 |
The invention relates to a method for the production of L-carnitine, wherein a β- lactone, which is a 4-(halomethyl)oxetane-2-one, is converted into carnitine with trimethylamine (TMA), wherein the β-lactone is not subjected to a basic...
|
|
WO/2012/010296 |
The invention relates to a method for the production of L-carnitine, wherein a chiral β-lactone carnitine precursor is obtained by a [2+2] cycloaddition of ketene with an aldehyde X-CH2-CHO, wherein X is selected from CI, Br, I and trim...
|
|
WO/2012/010651 |
The present invention relates to method for the preparation of an ω-amino-alkane(thio)amide having the formula (3). Furthermore, novel intermediates and partial reaction steps of the claimed method are disclosed.
|
|
WO/2012/010651 |
The present invention relates to method for the preparation of an ω-amino-alkane(thio)amide having the formula (3). Furthermore, novel intermediates and partial reaction steps of the claimed method are disclosed.
|
|
WO/2012/007814 |
A ternary co-crystal consisting of 1 :0.5:0.5 molar proportion of (S)-1,1'-bi-2-naphthol, 3(S)-propyl-4-[(S)1 '-phenyl-ethylamino]-butanoic acid and 3(R)-propyl-4-[(S)1'- phenyl-ethylamino]-butanoic acid having characteristic powder X-ra...
|
|
WO/2012/002203 |
Disclosed is a production method for obtaining an optically active β-aminocarbonyl compound by a Mannich reaction of an aldimine in which nitrogen is protected and a malonic acid diester, in the presence of optically active BINOL and 1-...
|
|
WO/2012/002465 |
Disclosed are: a material for a liquid crystal alignment film, which does not undergo film detachment or scratching during rubbing even when the material is burned at a temperature of 200˚C or lower and can achieve good liquid crystal a...
|
|
WO/2011/160730 |
The invention relates to a method for producing omega-amino acids or their esters, the method being characterized by the following steps: (a) ozonolysis of unsaturated fatty acids or fatty acid derivatives; (b) reductive amination of the...
|
|
WO/2011/158720 |
Disclosed is a method for efficiently producing a (1R, 2S)-1-amino-2-vinyl cyclopropane carboxylic acid ester, which is useful as a pharmaceutical intermediate, at low cost. Specifically, a (1R, 2S)-1-amino-2-vinyl cyclopropane carboxyli...
|
|
WO/2011/154333 |
The invention relates to a process for preparing crystalline 3,6,9-triaza-3,6,9-tris(carboxymethyl)-4-(4-ethoxybenzyl)und
ecanedioic acid of the formula (I) by hydrolysis of di-tert-butyl 3,6,9-triaza-3,6,9-tris(tert-butoxycarbonylmethyl...
|
|
WO/2011/154148 |
The invention discloses a number of therapeutic compounds and a method of treating a disorder in mammal.
|
|
WO/2011/152657 |
The present invention relates to acetyl-L-carnitine malate, a process for preparing the same, and a pharmaceutical composition comprising the same. The acetyl-L-carnitine malate of the present invention has good stability, solubility, an...
|
|
WO/2011/152657 |
The present invention relates to acetyl-L-carnitine malate, a process for preparing the same, and a pharmaceutical composition comprising the same. The acetyl-L-carnitine malate of the present invention has good stability, solubility, an...
|
|
WO/2011/151517 |
The present invention relates to a process for the preparation of a mixture of aspartic acid diethoxy succinate and an amino acid derivative of the general formula (I) wherein n is 1-10, m is 0 or 1, and R is hydrogen or an alkali metal ...
|
|
WO/2011/153493 |
The present invention relates to a cationic lipid having one or more biodegradable groups located in the mid- or distal section of a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorpora...
|
|
WO/2011/151519 |
The present invention relates to a method for recovering lanthanoid catalyst from the preparation of aspartic acid diethoxy succinate comprising contacting a carbonate source with a solution containing lanthanoid ions derived from said p...
|
|
WO/2011/148297 |
The present invention refers to the compounds corresponding to the following general formula (I): (I) wherein: R = C4-C8 alkanoyl; and X = NH-R1 where R1 = H, or an amine protecting group; and/or the pharmaceutically acceptable salts the...
|
|
WO/2011/147254 |
Provided are phenylbutyryl curcumin derivatives, their preparation methods, pharmaceutical compositions containing said derivatives and uses thereof for preparing anti-tumor drugs. Said curcumin derivatives are specifically 4-[bis(2-chlo...
|
|
WO/2011/141705 |
The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel cationic lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic ...
|
|
WO/2011/141703 |
The present invention provides compositions and methods for the delivery of interfering RNAs such as siRNAs that silence APOB expression in cells such as liver cells. In particular, the nucleic acid-lipid particles provide efficient enca...
|
|
WO/2011/141409 |
The application relates to novel substituted 8-alkoxy-2-aminotetralin derivatives, methods for the production thereof, the use thereof for the treatment and/or prevention of diseases, and the use thereof for producing medicaments used fo...
|
|
WO/2011/141704 |
The present invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel cationic lipids and nucleic acid- lipid particles that provide efficient encapsulation of nucleic...
|
